top of page
Colorful Disks

Luciferase Reporter Cell Lines for Monitoring
TF Transactivation

Our Luciferase Reporter Stable cell lines are genetically engineered to express luciferase during the activation of specific TFs Binding and Activation to provide an efficient approach to study and monitor various cellular processes, including gene regulation and signaling pathways.

We offer a wide selection of validated Firefly luciferase reporter cell lines that measure transcription factor activity as a read-out for various signaling pathways.

We also offer Gaussia luciferase reporter cell lines, a special type of luciferase that is naturally secreted from cells, which allows for the easy measurement of reporter activity directly in the media without any need to harvest the cells. 

 

Principle

TF luciferase reporter stable cell line utilizes a specially engineered promoter constructs to drive luciferase expression.  The promoter region consists of multiple repeats of a cis-element TF binding site, a DNA fragment from the promoter region of a known TF-targeted gene, or a DNA fragment containing putative or known TF binding sites. TF activation can occur through various mechanisms, such as extracellular stimuli or intracellular signaling pathways. Upon activation, the TF translocates to the nucleus, often interacting with relevant co-factors to promote luciferase gene expression. The resulting luciferase activity produces light in an enzymatic assay, with the intensity of the light directly correlating to the level of TF activation.

 

We offer two luciferase reporter systems: Firefly Luciferase and Gaussia Luciferase. Firefly luciferase is a widely used, reliable system that generates a bright, stable signal for gene expression detection. Gaussia luciferase, derived from Gaussia princeps, is a second-generation reporter that is secreted into the culture medium, eliminating the need for cell lysis. This enables non-invasive, continuous monitoring of TF activity while providing higher sensitivity and stability compared to Firefly or Renilla luciferases.

Firefly Luciferase (1).png
Gaussia diagram.png

Benefits

High Sensitivity and Responsiveness

Each cell line is validated to induce a strong reporter signal in response to stimuli, and is highly responsive to our Firefly Luciferase Substrate.

Mycoplasma Free

All cell lines have been tested negative for mycoplasma.

Consistent

The TF reporter construct is stably integrated into the genome to avoid cell-to-cell variations in experiments.

We offer cost-effective yet highly sensitive Luciferase Substrates for both Firefly and Gaussia luciferases.

Efficient

 

Cell lines can be used right away for experiments to study different signaling pathways.

Signaling Pathways

Cell Lines

Androgen Receptor/ AR

Targeted therapies for prostate cancer and other androgen-related diseases.

Calcineurin/NFAT
T Cell Activation

Activation of T Cells in immune response via calcium signaling.

ER Stress/ATF4
ATF6/CHOP/ERSE

 

Development of treatments for type 2 diabetes and neurodegenerative disorders.

Glucocorticoid
Receptor/GR

Development of treatments for autoimmune and inflammatory diseases.

Hypoxia
HIF

Development of treatments for cancer and ischemic diseases.

Inflammation
NF-κB

Development of treatments for cancer, diabetes, and inflammation.

JAK/STAT1/2
IFNα/ISRE

Development of treatments for cancer and autoimmune disorders.

MAPK/ERK
ELK

Development of treatments for cancer and autoimmune disorders.

Metabolism
FXR/RAR/AARE

Development of drugs for treating various metabolic diseases, including liver disease and diabetes.

SMAD 2/3/4
TGF-β

Development of treatments for cancer and fibrosis.

Wnt/β-Catenin
TCF/LEF

Development of treatments for cancer and bone disorders.

Antioxidant Pathway/ NRF2

Development of treatments for Alzheimer's, Parkinson's, and cancer.

cAMP/PKA
CREB

Development of drugs for treating various diseases, including cancer, diabetes, and inflammation.

Estrogen
Receptor

Targeted therapies for breast cancer and other estrogen-related diseases.

Heavy Metal Stress
MRF

Development of treatments for heavy metal toxicity.

Immune Response
IRF

Development of treatments for autoimmune and inflammatory diseases.

JAK/STAT1
IFNgamma

Development of drugs for treating various diseases, including cancer and autoimmune disorders.

JAK/STAT3
 

Development of drugs for treating various diseases, including cancer and inflammation.

MAPK/JNK
AP-1

Development of drugs for treating various diseases, including cancer, diabetes, and inflammation.

DNA Damage
p53

Development of treatments for cancer and genetic disorders.

SMAD 1/5/8
BMP

Development of treatments for bone and cartilage disorders.

Xenobiotic Stress
Toxicity/XRE/AHR

Development of treatments for xenobiotic toxicity and related diseases.

Signaling Pathways

Browse

bottom of page